Exclusive Licence Agreement Sample Contracts
EX-4.16 7 d654369dex416.htm EX-4.16Exclusive Licence Agreement • May 5th, 2020 • Delaware
[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed.
Standard Contracts
Exclusive Licence for Inside Media Group LtdExclusive Licence Agreement • October 10th, 2022
Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. CONFIDENTIAL – EXECUTION VERSION Exclusive Licence...Exclusive Licence Agreement • December 18th, 2014 • Ascendis Pharma a/S • Pharmaceutical preparations
[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
ContractExclusive Licence Agreement • May 10th, 2023
Proteomics International and Sonic Healthcare USA sign exclusive licence agreement to take PromarkerD to the US market
Shield Therapeutics and Norgine B.V. (Norgine) enter into an exclusive licence agreement for the commercialisation of Feraccru® in Europe, Australia and New ZealandExclusive Licence Agreement • December 30th, 2018
This long-term exclusive licence grants Norgine the right to commercialise Feraccru® in the UK, France, Germany, Italy, Spain and all other European countries which are not already covered by Shield's previously announced licence agreements with AOP Orphan Pharmaceuticals AG and Ewopharma AG, as well as in Australia and New Zealand (the "Licensed Territories").
EXCLUSIVE LICENCE AGREEMENTExclusive Licence Agreement • March 25th, 2015
This licence, effective , (“Effective Date”) is between [add name and address of the University] (the “University”) and the party set out in Schedule 1 (the “Licensee”).
EXCLUSIVE LICENCE AGREEMENTExclusive Licence Agreement • August 22nd, 2005 • Pharmaxis Ltd. • American depositary receipts • Australian Capital Territory
PRAXIS PHARMACEUTICALS AUSTRALIA PTY LTD A.C.N. 082 811 630 having its registered office at Duesbarys, 60 Marcus Clarke Street, Canberra City A.C.T. 2601
Exclusive Licence Agreement PharmaSynth Pty Ltd PharmaSynth Global Transbiotech Inc GTB Clayton Utz Lawyers Level 28 Riparian Plaza 71 Eagle Street Brisbane QLD 4000 Australia GPO Box 55 Brisbane QLD 4001 T + 61 7 3292 7000 F + 61 7 3221 9669...Exclusive Licence Agreement • December 30th, 2009 • Progen Pharmaceuticals LTD • Medicinal chemicals & botanical products • California
Parties PharmaSynthPharmaSynth Pty Ltd, ABN 48 074 656 509, of 2806 Ipswich Road, Darra, QLD, Australia (“PharmaSynth”), a wholly-owned subsidiary of Progen Pharmaceuticals Ltd
Easy Access IP Exclusive Licence AgreementExclusive Licence Agreement • July 9th, 2013 • New South Wales
This licence, effective , ("Effective Date") is between NewSouth Innovations Pty Ltd, ABN 25 000 263 025 of Rupert Myers Building, Gate 14 Barker St, UNSW Sydney NSW 2052, Australia (“NSi”), a wholly owned subsidiary of The University of New South Wales (“University”), and the party set out in the attached Schedule (the "Licensee").
Oxford BioMedica and Axovant Worldwide Exclusive Licence Agreement for OXB-102 for Parkinson’s diseaseExclusive Licence Agreement • June 5th, 2018
This presentation does not constitute an offer to sell or a solicitation of offers to buy Ordinary Shares (the “Securities”). Although reasonable care has been taken to ensure that the facts stated in this presentation are accurate and that the opinions expressed are fair and reasonable, the contents of this presentation have not been formally verified by Oxford BioMedica plc (the “Company”) or any other person. Accordingly, no representation or warranty, expressed or implied,
ContractExclusive Licence Agreement • November 6th, 2014 • Cti Biopharma Corp • Pharmaceutical preparations • England
** Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
NATIONAL UNIVERSITY OF IRELAND MAYNOOTH, MAYNOOTH UNIVERSITY and EXCLUSIVE LICENCE AGREEMENTExclusive Licence Agreement • September 29th, 2022
NATIONAL UNIVERSITY OF IRELAND MAYNOOTH, MAYNOOTH UNIVERSITY whose principal address is at Maynooth, County Kildare, Ireland (the “University”); and
CONTINUATION OF EXCLUSIVE LICENCE AGREEMENT BETWEEN DURISOL RESOURCE INC. AND SMITH-MIDLAND CORPORATIONExclusive Licence Agreement • April 14th, 2000 • Smith Midland Corp • Concrete products, except block & brick • Ontario
ContractExclusive Licence Agreement • March 22nd, 2017
BACKGROUND The South Downs National Park Authority and The South Downs National Park Trust are working together to establish a financially stable, independent charity to support the South Downs National Park’s Partnership Management Plan. As part of this agreement the South Downs National Park Authority grants an Exclusive Licence to use the Intellectual Property of The South Downs National Park Authority and sets out the standard terms and conditions that will be incorporated and apply to the Licence granted. Applicant Details Organisation/Name South Downs National Park Trust Address South Downs Centre, North Street, Midhurst, West Sussex, GU29 9DH Trade Marks
